What is Anoro Ellipta?
Anoro Ellipta is a once-daily, fixed-dose combination inhaler containing umeclidinium 62.5 mcg (a long-acting muscarinic antagonist/LAMA) and vilanterol 25 mcg (a long-acting beta2-agonist/LABA) indicated for maintenance treatment of chronic obstructive pulmonary disease (COPD). 1
Drug Composition and Delivery
Anoro Ellipta is delivered via the Ellipta dry powder inhaler device, which contains two separate foil blister strips—one with umeclidinium bromide and one with vilanterol trifenatate. 1 When activated, the device delivers approximately 55 mcg of umeclidinium and 22 mcg of vilanterol per inhalation. The lactose-based powder formulation contains milk proteins, which is relevant for patients with milk protein allergies. 1
Mechanism of Action
This dual bronchodilator works through complementary mechanisms:
- Umeclidinium blocks muscarinic receptors in airway smooth muscle, preventing acetylcholine-mediated bronchoconstriction
- Vilanterol stimulates beta2-adrenergic receptors, causing direct bronchodilation and relaxation of airway smooth muscle
The combination provides additive bronchodilatory effects superior to either component alone. 1
Clinical Indications and Positioning
Anoro Ellipta is specifically indicated for maintenance treatment of airflow obstruction in COPD patients, including those with chronic bronchitis and/or emphysema. 1 According to the 2023 Canadian Thoracic Society guidelines, LAMA/LABA combinations like umeclidinium/vilanterol are recommended for patients with persistent moderate to severe dyspnea despite single bronchodilator therapy. 2
Critical Limitations
- NOT indicated for relief of acute bronchospasm 1
- NOT indicated for treatment of asthma 1
- Should not be used as rescue medication
Clinical Efficacy
Umeclidinium/vilanterol demonstrates superior efficacy compared to:
- Placebo and individual components (umeclidinium or vilanterol alone) 2
- Once-daily tiotropium monotherapy 3
- Twice-daily salmeterol/fluticasone combination 3
The combination improves multiple clinical outcomes including lung function (FEV1), dyspnea scores, rescue medication use, exacerbation rates, and health-related quality of life. 3, 4
Safety Profile
The medication is generally well-tolerated with:
- Most common adverse events: headache and nasopharyngitis 3
- No clinically relevant increased cardiovascular risk in pooled trial data 3
- Overall adverse event incidence of approximately 28.8% in real-world Korean surveillance data 5
- Serious adverse events occurring in approximately 5.9% of patients 5
Dosing Considerations
The standard dose is one inhalation once daily, with no adjustment needed for:
- Geriatric patients 1
- Patients with renal impairment (including severe CrCl <30 mL/min) 1
- Patients with moderate hepatic impairment 1
Important Caveats
Patients with severely compromised lung function (FEV1 <30% predicted) can generate adequate inspiratory flow (mean 66.5 L/min) through the Ellipta device, though actual drug delivery depends on individual inspiratory flow profiles. 1
Practical Advantages
The once-daily dosing schedule and easy-to-use Ellipta inhaler device may improve medication adherence compared to multiple-times-daily regimens or more complex inhaler devices. 3, 6 This represents a significant practical advantage in COPD management where adherence is often suboptimal.